VEGFA and hepatocellular carcinoma: The treatment options in 2023 for first-line treatment for HCC include targeted therapies such as multikinase inhibitors (MKI), anti-VEGF therapies, immune checkpoint inhibitors (ICIs), or combinations of these (Table 4).